As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Armata Pharmaceuticals, Inc. The largest reported stake is Innoviva, Inc.'s, at 82.7%. 3 filings are on record since August 12, 2025 (Schedule 13D/A, May 13, 2026).
Sell to companies like Armata Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Innoviva, Inc. · Percent: 82.7% · SCHEDULE 13D/A
- · Holder: Innoviva, Inc. · Percent: 83.1% · SCHEDULE 13D/A
- · Holder: Innoviva, Inc. · Percent: 83.3% · SCHEDULE 13D/A
Armata Pharmaceuticals, Inc. has 3 Schedule 13D or 13G filings on record since 2025-08-12. 1 holder's latest filing reports 5% or more of common stock, $0.01 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Innoviva, Inc. | 82.7% | 55,467,459 | SCHEDULE 13D/A, 2026-05-13 | 2026-05-12 |
Holding shares or following this stake? See who's behind Armata Pharmaceuticals, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Armata Pharmaceuticals, Inc. and the records around it.
Armata Pharmaceuticals, Inc. elsewhere on the record
- Leadership changes Jul 2026
- Who owns it
Watch Armata Pharmaceuticals, Inc.
Get an email when Armata Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Armata Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Armata Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Armata Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Innoviva, Inc.
Item 4 in Schedule 13D is hereby supplemented as follows: On May 12, 2026, the Issuer entered into, as borrower, a credit and security agreement (the "May 2026 Credit Agreement") with Innoviva Sub, as lender, pursuant to which the Issuer borrowed from Innoviva Sub $25,000,000. On the date of this Amendment No. 15, the Reporting Persons collectively own 25,076,769 shares of Common Stock of the Issuer, warrants to acquire an additional 10,653,847 shares of Common Stock of the Issuer, and the right to acquire an additional 19,736,843 shares of Common Stock of the Issuer upon conversion of the convertible loan (excluding any accrued interest).Item 4 of the SCHEDULE 13D/A filed 2026-05-13
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-12 | Innoviva, Inc. | 83.3% | SCHEDULE 13D/A |
| 2026-01-26 | Innoviva, Inc. | 83.1% | SCHEDULE 13D/A |
| 2026-05-13 | Innoviva, Inc. | 82.7% | SCHEDULE 13D/A |
Questions about who owns Armata Pharmaceuticals, Inc.
Who owns Armata Pharmaceuticals, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Armata Pharmaceuticals, Inc.: Innoviva, Inc. (82.7%, Schedule 13D/A, filed 2026-05-13).
When did Innoviva, Inc. buy into Armata Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Innoviva, Inc. on this page is the Schedule 13D/A, filed 2025-08-12, reporting 83.3%; its latest, Schedule 13D/A filed 2026-05-13, reports 82.7%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Armata Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 20, 2026 | Leadership change: David House appointed, Chief Financial Officer | — | Leadership changes | Source |
| June 24, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| April 27, 2026 | Leadership change: Daniel Gilmer appointed, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Armata Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.